Robeco Institutional Asset Management B.V. Purchases 3,555 Shares of Medpace Holdings, Inc. $MEDP

Robeco Institutional Asset Management B.V. raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,565 shares of the company’s stock after acquiring an additional 3,555 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.07% of Medpace worth $10,060,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of MEDP. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Employees Retirement System of Texas bought a new stake in Medpace in the 2nd quarter valued at $36,000. IFP Advisors Inc raised its stake in shares of Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after buying an additional 134 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of Medpace by 5,075.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after buying an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Medpace by 514.3% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after acquiring an additional 180 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity

In related news, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is owned by corporate insiders.

Medpace Trading Down 0.8%

NASDAQ:MEDP opened at $595.00 on Friday. The stock has a market capitalization of $16.76 billion, a P/E ratio of 41.61, a price-to-earnings-growth ratio of 2.02 and a beta of 1.43. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $626.26. The firm has a 50 day moving average of $581.05 and a 200-day moving average of $499.64.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the company earned $3.01 EPS. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MEDP shares. Barclays upped their target price on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.